Tissue factor pathway inhibitor is the main determinant of thrombin generation in haemophilic patients.
coagulation
haemophilia
multiple linear regression
thrombin generation
tissue factor pathway inhibitor
Journal
Haemophilia : the official journal of the World Federation of Hemophilia
ISSN: 1365-2516
Titre abrégé: Haemophilia
Pays: England
ID NLM: 9442916
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
24
05
2018
revised:
14
12
2018
accepted:
14
12
2018
pubmed:
29
1
2019
medline:
30
4
2019
entrez:
29
1
2019
Statut:
ppublish
Résumé
The thrombin generation (TG) assay evaluates haemostatic balance, which is influenced by the levels of many coagulation factors and inhibitors. Our objective was to identify the determinant factors of TG in haemophilia A (HA) and haemophilia B (HB) patients and to compare them to those in healthy controls. Coagulation factor and inhibitor levels, and TG, were measured in platelet-poor plasma from 40 patients with HA, 32 patients with HB and 40 healthy subjects. Data were analysed using multiple regression models. In HA patients, factor VIII was a positive determinant of endogenous thrombin potential (ETP) and peak, whereas tissue factor pathway inhibitor (TFPI) and factor V were negative determinants of ETP and peak. In HB patients, FIX was a positive determinant of ETP and peak, FVII being a positive determinant of peak. Antithrombin and protein S (PS) were negative determinants of ETP while FX was a negative determinant of peak. Above all, in HB patients, TFPI was a negative determinant of ETP and peak. In healthy subjects, FVIII was a positive determinant of ETP and peak, whereas FX and protein S were negative determinants of these parameters. TFPI was not a negative determinant of either peak or ETP. In haemophilic patients, the determinant factors of TG are all implicated in FXa generation and inhibition, the crucial determinant factor being TFPI whatever the type of haemophilia, A or B. These findings contribute to the rationale that recently place TFPI as a target for innovative therapies of haemophilia.
Substances chimiques
Blood Coagulation Factors
0
Lipoproteins
0
lipoprotein-associated coagulation inhibitor
0
Fibrinogen
9001-32-5
Thrombin
EC 3.4.21.5
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-348Subventions
Organisme : Pfizer
ID : WI193434
Informations de copyright
© 2019 John Wiley & Sons Ltd.